Obesity & Diabetes
Rosiglitazone does not prevent free fatty acid-induced insulin resistance in obesity
Published in Obesity and Diabetes Week, October 31st, 2005
"Elevation of free fatty acids (FFAs) by the infusion of triglyceride-heparin emulsion infusion (TG-Hep) causes insulin resistance (IR). We examined the effect of insulin sensitizer (rosiglitazone) on FFA-induced IR. Nine obese subjects underwent a 6-hour infusion of TG-Hep before and after 6 weeks of rosiglitazone (8 mg/d) treatment. Hyperinsulinemic euglycemic clamps were performed during 0-2 and 4-6 hours of TG-Hep," scientists in the United States report.
"After rosiglitazone for 6 weeks, fasting FFA concentration fell, but not significantly...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Therapy
Treatment with metformin and insulin does not affect adiponectin levels - Obesity & Diabetes
Exercise without weight loss is effective for obesity reduction in type 2 diabetes - Obesity & Diabetes
Increased fat compensates for insulin resistance in abdominal obesity and type 2 diabetes - Obesity & Diabetes
Low adiponectin in African Americans linked to insulin sensitivity in children - Adipose Tissue
Age and gender effects found in adipose tissue of subjects at risk for type 2 diabetes - Alzheimer Disease
Midlife obesity may be associated with risk of dementia and Alzheimer disease - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
